GlassScriptPhysician profile
Hilda Daniel
NPI 1063421121
$14,792.14
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $138 · 2021: $3,109.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $10,569.39 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $3,608.76 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $163.19 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $138.49 | 2019 | |
| Sunovion Pharmaceuticals INC. | $94.40 | 2019-2020 | |
| Lundbeck LLC | $60.29 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.43 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $36.22 | 2019-2020 | |
| Shire North American Group INC | $23.70 | 2019 | |
| Adlon Therapeutics L.P. | $22.46 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.88 | 2019 | |
| Tris Pharma INC | $16.93 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hilda Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.